Key facts
- This page summarizes David A. Scheinberg's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jan 2025, 17:34.
David A. Scheinberg - 10 Jan 2025 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)
- Reporting relationship
- Director
- Issuer ticker
- SLS
- Reported as of
- 10 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jan 2025, 17:34:08 UTC
- Prior SEC filing
- 25 Jan 2024
- Next SEC filing
- 09 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ David A. Scheinberg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David A. Scheinberg filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 14 Jan 2025.
Change
- Previous filing in this sequence was filed on 25 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- +118%
- Price
- $0.000000
- Shares after
- 23,082
- Date
- 10 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +18,500
- Change %
- Price
- $0.000000
- Shares after
- 18,500
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,500
- Exercise price
- $0.9525
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Footnote F2
The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney